Final Programme - iuphar

FC02 Transmembrane transport: Perspectives for disease and drug discovery
Mon 09:30 FC02.1 Molecular structure and pharmacology of membrane transporters
Mon 14:30 FC02.2 Membrane transporters and disease
Tue 09:30 FC02.3 Intestinal and hepatic transporters
Tue 14:30 FC02.4 Membrane transporters: Molecular genetics and pharmacogenetics
FC03 Ion channels in analgesia and anaesthesia
Mon 09:30 FC03.1 Ion channel drug targets in the sensory nerve
Mon 14:30 FC03.2 Voltage-operated calcium channels as targets for analgesic action
Tue 09:30 FC03.3 Synaptic plasticity in analgesia-related pathways
Tue 14:30 FC03.4 Ion channels as molecular targets for general anaesthetics
FC04 Pharmacoepidemiology, current controversies and opportunities
Mon 09:30 FC04.1 Methodological issues in pharmacoepidemiology
Mon 14:30 FC04.2 Approaches to screening electronic medical records and claims data
Tue 09:30 FC04.3 Regulatory challenges in managing risk of medicinal products
Tue 14:30 FC04.4 In utero exposure to drugs
FC05 Translational science in the metabolic syndrome:
Basic and clinical pharmacology
Mon 09:30 FC05.1 New molecular targets in metabolic syndrome
Mon 14:30 FC05.2 Translational science in the metabolic syndrome: Basic and clinical pharmacology
Tue 09:30 FC05.3 Normalizing blood glucose in metabolic syndrome I: GLP-1 analogues and DPP IV
inhibitors
Tue 14:30 FC05.4 Normalizing blood glucose in metabolic syndrome II: Glitazones and metformin
FC06 The heart gone wrong; stabilization of cardiac function
Mon 09:30 FC06.1 Molecular mechanisms of arrhythmia
Mon 14:30 FC06.2 Novel anti-arrhythmics
Tue 09:30 FC06.3 Novel treatments for systolic heart failure
Tue 14:30 FC06.4 Treatment options for diastolic heart failure
FC07 Simulation and data modelling in drug development. Better drugs faster?
Mon 09:30 FC07.1 Modelling and simulation – how and why
Mon 14:30 FC07.2 Disease models – using virtual organs and patient populations
Tue 09:30 FC07.3 Modelling and simulation in clinical drug development
Tue 14:30 FC07.4 Modelling and simulation – A regulator’s view
FC08 Developments in the treatment of sexual dysfunction and diseases of the lower
urinary tract
Mon 14:30 FC08.1 Treatment of sexual dysfunction associated with cardiovascular disease
Tue 09:30 FC08.2 Pharmacological treatment of lower urinary tract syndrome/benign prostatic hyperplasia
Tue 14:30 FC08.3 Pharmacological treatment of bladder dysfunction
FC09 Inflammation and immunopharmacology: New tools for old diseases
Mon 09:30 FC09.1 Steroids and beyond: Novel treatments for asthma and allergy
Mon 14:30 FC09.2 Biologicals in inflammatory diseases – successes, promises and problems
Tue 09:30 FC09.3 iNOS – nitric oxide pathway in inflammation and as a target of anti-inflammatory
treatment
Tue 14:30 FC09.4 NSAIDs and COX-2 inhibitors. Current strategies and future directions
Wed 09:30 FC09.5 Novel anti-inflammatory targets and mechanism
Programme outline 19